Delcath Systems (NASDAQ:DCTH) Upgraded to “Sell” at StockNews.com

StockNews.com upgraded shares of Delcath Systems (NASDAQ:DCTH) to a sell rating in a research report sent to investors on Wednesday morning.

Separately, HC Wainwright raised their price objective on Delcath Systems from $18.00 to $20.00 and gave the stock a buy rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of Moderate Buy and an average price target of $18.50.

Delcath Systems Stock Up 10.4 %

Shares of NASDAQ:DCTH opened at $5.09 on Wednesday. The business has a 50-day moving average price of $4.34 and a 200 day moving average price of $3.84. The company has a current ratio of 3.30, a quick ratio of 3.11 and a debt-to-equity ratio of 0.08. The company has a market capitalization of $112.21 million, a price-to-earnings ratio of -1.52 and a beta of 0.51. Delcath Systems has a 12-month low of $2.25 and a 12-month high of $7.99.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings data on Tuesday, March 26th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.19. The firm had revenue of $0.54 million during the quarter, compared to the consensus estimate of $0.48 million. Delcath Systems had a negative return on equity of 2,571.64% and a negative net margin of 2,079.17%. During the same period last year, the company earned ($0.86) EPS. Sell-side analysts expect that Delcath Systems will post -2.64 EPS for the current year.

Insider Activity at Delcath Systems

In other Delcath Systems news, Director Gil Aharon bought 26,882 shares of the firm’s stock in a transaction that occurred on Tuesday, March 19th. The stock was purchased at an average price of $3.72 per share, for a total transaction of $100,001.04. Following the completion of the purchase, the director now directly owns 1,069,710 shares in the company, valued at $3,979,321.20. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 21.10% of the stock is currently owned by company insiders.

Institutional Trading of Delcath Systems

A number of institutional investors have recently modified their holdings of DCTH. Tower Research Capital LLC TRC boosted its position in Delcath Systems by 107.8% during the first quarter. Tower Research Capital LLC TRC now owns 4,663 shares of the company’s stock worth $26,000 after purchasing an additional 2,419 shares in the last quarter. Millennium Management LLC acquired a new position in Delcath Systems in the second quarter valued at $40,000. Dimensional Fund Advisors LP acquired a new position in Delcath Systems in the first quarter valued at $75,000. Renaissance Technologies LLC acquired a new position in Delcath Systems in the first quarter valued at $70,000. Finally, GSA Capital Partners LLP acquired a new position in Delcath Systems in the third quarter valued at $63,000. 61.12% of the stock is currently owned by hedge funds and other institutional investors.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.